Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Modulation of Liver Metabolism/Inflammation at Different Disease Stages by Leveraging ADAR-based RNA Editing

Project description

Editing RNA to rethink liver disease therapy

Current treatments for liver disease are often reactive and do not address the molecular causes of the condition. The ERC-funded HepaModulatoR project aims to develop a more proactive model through RNA base editing. This allows for precise protein modification on an as-needed basis, avoiding the risks associated with permanent DNA changes. The project uses computational modelling and high-throughput screening to identify exactly where disease signals go wrong. By redirecting ADAR enzymes via RNA-based drugs, the team can ‘correct’ protein behaviour to stop inflammation or cancer progression in its tracks. This research marks a transition toward a new class of precision therapies.

Objective

RNA base editing, catalyzed by ADAR enzymes, is a natural process that diversifies protein function by modifying mRNA. Redirecting ADAR activity with RNA-based drugs holds significant promise for correcting genetic mutations and uniquely enables precise modulation of protein function. However, major challenges remain to fully unlock this potential.
In this collaborative effort, we present a target discovery platform and demonstrate in vivo proof-of-concept (PoC) that targeted RNA base editing can mitigate chronic liver disease. Our team combines its groundbreaking insights and tools to predict functional editing computationally (PI Levanon), efficiently screen for effective edits (PI Stafforst), and establish functional PoC in animal models of liver disease (PI Heikenwälder).
Chronic liver disease stems from disturbances in the liver microenvironment caused by chronic viral infections, alcohol intake, sedentary life-style/high-calorie diets or autoimmunity, all disrupt hepatocyte metabolism and regulatory signalling. This ultimately leads to liver inflammation, fibrosis, and liver cancer. We suggest that targeted RNA base editing is well-suited to counteract liver disease by modulating protein function and upregulating hepatoprotective proteins.
To maximize the likelihood of success, our team addresses three Focus Areas, each representing a distinct stage of liver disease: In Focus Area 1, we aim to modulate liver metabolism (promoting catabolism) at an early disease stage. In Focus Area 2, we seek to reduce chronic inflammatory signalling at the mid-stage. Finally, Focus Area 3 focuses on generating highly immunogenic neoantigens in cancerous liver tissue to stimulate immune therapies at advanced stages.
Overall, this project will push far beyond the current state-of-the-art in this field, significantly advancing this innovative therapeutic modality. We aim to make a substantial impact on Europe’s society, healthcare systems, and pharmaceutical industry.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-SYG - HORIZON ERC Synergy Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-SyG

See all projects funded under this call

Host institution

EBERHARD KARLS UNIVERSITAET TUEBINGEN
Net EU contribution
€ 7 470 484,25
Address
GESCHWISTER-SCHOLL-PLATZ
72074 Tuebingen
Germany
Region
Baden-Württemberg Tübingen Tübingen, Landkreis
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 7 470 484,25

Beneficiaries (2)